Hi Mer
Re' Price Sensitive
I think the price sensitive part has something to do with the 2 following statements found within the release:
1.
"Whilst acknowledging the rapid rise in clinical trials involving PD-1 and their combination with other treatments*, a PD-1 B-cell vaccination approach represents a paradigm shift in cancer immunotherapy."
* Tang etal. Comprehensive analysis of the clinical immuno-oncology landscape, Annals of Oncology, 2017
The above statement when read with the following excerpt from the release below is what I believe is the price sensitive part:
2.
"In industry-recognised mouse cancer models (colon cancer), the PD-1 targeting B-cell vaccine is more superior than the gold standard mouse PD-1 monoclonal antibody (used in preclinical model testing for Keytruda and Opdivo)."
I don't believe that the above information has been released prior to this release, the information surrounding the PD-1 B Cell mouse trial results being superior is ground breaking which I interpret as being price sensitive information.
fp
- Forums
- ASX - By Stock
- IMU
- Ann: Investor Presentation
Ann: Investor Presentation, page-43
-
-
- There are more pages in this discussion • 6 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMU (ASX) to my watchlist
(20min delay)
|
|||||
Last
3.9¢ |
Change
0.002(5.41%) |
Mkt cap ! $386.7M |
Open | High | Low | Value | Volume |
3.6¢ | 4.0¢ | 3.5¢ | $1.163M | 31.27M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
6 | 2275218 | 3.8¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
3.9¢ | 196677 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
18 | 5665336 | 0.018 |
14 | 3997559 | 0.017 |
6 | 2974375 | 0.016 |
10 | 3219799 | 0.015 |
4 | 497500 | 0.014 |
Price($) | Vol. | No. |
---|---|---|
0.019 | 400000 | 2 |
0.020 | 5410946 | 12 |
0.021 | 8494780 | 17 |
0.022 | 8757253 | 13 |
0.023 | 4826614 | 8 |
Last trade - 16.10pm 22/11/2024 (20 minute delay) ? |
IMU (ASX) Chart |